John Wilson
Director/Board Member chez MARKER THERAPEUTICS, INC.
Fortune : 7 M $ au 31/03/2024
Profil
Mr. John R.
Wilson is a Chief Executive Officer at Wilson Wolf Manufacturing Corp.
and an Independent Director at Marker Therapeutics, Inc. He is on the Board of Directors at Marker Therapeutics, Inc. Mr. Wilson was previously employed as an Independent Non-Executive Director by AlloVir, Inc., a Principal by Cellex Biosciences, Inc., and a Chief Executive Officer by Marker Cell Therapy, Inc. He received his undergraduate degree from Hamline University and an undergraduate degree from the University of Minnesota.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ALLOVIR INC
4,70% | 31/12/2023 | 5 355 877 ( 4,70% ) | 4 M $ | 31/03/2024 |
| 06/06/2023 | 781 200 ( 8,77% ) | 3 M $ | 31/03/2024 |
Postes actifs de John Wilson
| Sociétés | Poste | Début |
|---|---|---|
| MARKER THERAPEUTICS, INC. | Director/Board Member | 17/10/2018 |
Wilson Wolf Manufacturing Corp.
 Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Chief Executive Officer | 01/01/1998 |
Anciens postes connus de John Wilson
| Sociétés | Poste | Fin |
|---|---|---|
| ALLOVIR, INC. | Founder | 17/05/2022 |
| Cellex Biosciences, Inc. | Corporate Officer/Principal | - |
Marker Cell Therapy, Inc.
 Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Chief Executive Officer | - |
Formation de John Wilson
| Hamline University | Undergraduate Degree |
| University of Minnesota | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MARKER THERAPEUTICS, INC. | Health Technology |
| ALLOVIR, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Cellex Biosciences, Inc. | Distribution Services |
Wilson Wolf Manufacturing Corp.
Wilson Wolf Manufacturing Corp. Medical SpecialtiesHealth Technology Wilson Wolf Manufacturing Corp. is a private company based in St. Paul, MN that was founded in 1998 by John R. Wilson, who has been the CEO since then. The company specializes in developing and manufacturing innovative cell culture technologies, with a focus on advancing the field of cell and gene therapy through its patented G-Rex® bioreactor technology. The G-Rex® product line has experienced an average annual sales growth rate of 50% over the last 5 years and is commonly used in every phase of cell and gene therapy manufacturing. In 2020, Wilson Wolf formed a joint venture with Bio-Techne and Fresenius-Kabi called ScaleReady to bring more capacity to advance the cell and gene therapy field. The company's patented products and protocols are used for numerous applications, including monoclonal antibody production, corneal transplants, porcine heart valve testing, mesenchymal cell production, and islet transplants for type 1 diabetes. The company's technology represents a paradigm shift in cell culture devices, resulting in a process for cell culture that is less costly and more effective. | Health Technology |
Marker Cell Therapy, Inc.
Marker Cell Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Marker Cell Therapy, Inc. develops clinical stage immuno-oncology therapies. The company is headquartered in New Brighton, MN. | Commercial Services |
